Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-17-005422
Filing Date
2017-05-17
Accepted
2017-05-17 16:57:10
Documents
1
Period of Report
2017-05-15

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f3051517oloughlin_actinium.html 3  
1 OWNERSHIP DOCUMENT f3051517oloughlin_actinium.xml 3 5486
  Complete submission text file 0001213900-17-005422.txt   6938
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 955 HARTMAN RUN ROAD MORGANTOWN WV 26507
Business Address
O'Loughlin Steve (Reporting) CIK: 0001615840 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36374 | Film No.: 17852287